In this Issue:
BRCA1 and BRCA2 mutations and risk of breast and ovarian cancer
HRT and ovarian cancer risk
Olaparib + chemotherapy for recurrent platinum-sensitive ovarian cancer
Pazopanib + paclitaxel vs paclitaxel alone for platinum-resistant or platinum-refractory advanced ovarian cancer
Outcomes with aggressive surgery in patients with advanced-stage ovarian cancer
Prognostic value of histological type in stage IV ovarian carcinoma
Risk prediction model for ovarian cancer
A modified IV/IP chemotherapy regimen for optimally debulked stage III ovarian cancer
Antiestrogen therapy in platinum-resistant ovarian cancer patients
Metabolic parameters predict survival after relapse in patients with relapsed epithelial ovarian cancer
Please login below to download this issue (PDF)